Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 30, 2025 07:00 ET | Source: Sionna Therapeutics, Inc.

Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025

WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm...
March 20, 2025 07:00 ET | Source: Sionna Therapeutics, Inc.

Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline...
February 24, 2025 08:00 ET | Source: Sionna Therapeutics, Inc.

Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic...
February 10, 2025 16:03 ET | Source: Sionna Therapeutics, Inc.

Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

BOSTON, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic...
February 06, 2025 19:51 ET | Source: Sionna Therapeutics, Inc.

Sionna Therapeutics Prices Upsized Initial Public Offering

BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic...